Skip to main content


10-10-2017 | Lymphoma | Highlight | Article

Editor's pick

Post-HSCT maintenance rituximab improves mantle-cell lymphoma survival

Maintenance treatment with the anti-CD20 antibody rituximab after induction immunochemotherapy and autologous hematopoietic stem-cell transplantation is associated with a significant survival benefit among young patients with mantle-cell lymphoma, phase III trial findings show.


N Engl J Med 2017; 377: 1250–1260

06-10-2017 | Lymphoma | News | Article

Editor's pick

Obinutuzumab may improve follicular lymphoma outcome

Treatment with obinutuzumab-based chemotherapy prolongs progression-free survival over rituximab-based therapy in patients with follicular lymphoma, GALLIUM trial data suggest.


N Engl J Med 2017; 377: 1331–1344, 1389–1390

20-09-2017 | Lymphoma | Main feed | News


Copanlisib, low-dose cabazitaxel receive FDA go ahead

Click through to read more on these approvals

24-08-2017 | Oncology | News | Article

Crizotinib shows promise in pediatric ALCL and IMT

Pediatric patients with anaplastic large cell lymphomas and inflammatory myofibroblastic tumors respond well to crizotinib therapy, with more than 80% experiencing an objective response, US researchers report.


J Clin Oncol 2017; Advance online publication

07-07-2017 | Lymphoma | Main feed | News


Rituximab–hyaluronidase human combination approved for multiple indications

Click through to read a round-up of recent US FDA approvals

19-05-2017 | Oncology | News | Article

In other news

Here we report on osteoporosis therapy in breast cancer patients, the feasibility of an alternative formulation of rituximab in follicular lymphoma, the effects of extended use of anamorelin on lung cancer-related cachexia, and the 3-year results of the COMBI-d trial.

image credits